bluuebunny/crossref_metadata_2025_split huggingface dataset:
ChemInform Abstract: Synthesis and Biological Activity of Pyrido[3′,2′:4,5]furo[3,2‐d]pyrimidine Derivatives as Novel and Potent Phosphodiesterase Type 4 Inhibitors.
Authors: Pages Lluis , et al. et al. 
Published: January 2012

AbstractTitle compounds (X) and (XIV) are tested for phosphodiesterase type 4 (PDE4) inhibitory activity, with the potential to treat asthma and chronic obstructive pulmonary disease.
ChemInform Abstract: Synthesis, Hypnotic Properties and Molecular Modeling Studies of 1,2,7,9‐Tetraaza‐spiro[4.5]dec‐2‐ene‐6,8,10‐triones.
Authors: Girgis Adel S. , Farag Hanaa , Ismail Nasser S. M. , George Riham F. 
Published: January 2012

Abstract1,3‐Dipolar cycloaddition reaction of pyrimidinetriones (I) with in situ generated nitrilimines affords title compounds (III) in a highly regioselective manner.
ChemInform Abstract: Anticancer and Radio‐Sensitizing Evaluation of Some New Thiazolopyrane and Thiazolopyranopyrimidine Derivatives Bearing a Sulfonamide Moiety.
Authors: Ghorab Mostafa M. , Ragab Fatma A. , Heiba Helmy I. , El‐Hazek Reham M. 
Published: January 2012

AbstractAll newly synthesized compounds are screened for their in vitro anticancer activity against human breast cancer cell line MCF7.
ChemInform Abstract: Cyclization Reactions of Hydrazones. Part 32. Synthesis of Some Pyrazolylhydrazones and Study of Their Cyclization.
Authors: Cankar Petr , Malon Michal , Gucky Tomas , Slouka Jan 
Published: January 2012

AbstractSeveral substituted 1H‐pyrazol‐5‐yl hydrazones (III) are prepared in order to study their cyclization reactions.
ChemInform Abstract: Novel Synthetic Methodologies. Part 6. Synthesis of 3,6‐Epoxy[1,5]dioxocines from 2‐Hydroxyaromatic Benzaldehydes.
Authors: Sashidhara Koneni V. , Kumar Abdhesh , Rao K. Bhaskara 
Published: January 2012

AbstractBase‐mediated reaction of 2‐hydroxybenzaldehydes with chloromethyloxirane provides pharmaceutically relevant new title compounds of type (III) (16 examples).
ChemInform Abstract: Ruthenium‐Catalyzed C—H Silylation of Methylboronic Acid Using a Removable α‐Directing Modifier on the Boron Atom.
Authors: Ihara Hideki , Ueda Akinori , Suginome Michinori 
Published: January 2012

Abstractα‐Silylation of methylboronic acid (II) with silyl hydrides (IV) is achieved using pyrazolylaniline (Ia) as a removable α‐directing modifier on the boron atom.
ChemInform Abstract: Enantioselective Synthesis of α‐Aminophosphonates via Organocatalytic Sulfenylation and [2,3]‐Sigmatropic Sulfimide Rearrangement.
Authors: Armstrong Alan , Deacon Neil , Donald Craig 
Published: January 2012

AbstractA combination of sulfenylation and Wittig‐type olefination gives enantioenriched allyl sulfides of type (IV).
ChemInform Abstract: The Application of Tandem Aza‐Wittig Reaction to Synthesize Artemisinin—Guanidine Hybrids and Their Antitumor Activity.
Authors: Xie Lijun , Zhao Yanfang , Zhai Xin , Li Peng , Liu Chun , Li Yangxiong , Gong Ping 
Published: January 2012

AbstractTitle compounds (I)‐(III) show enhanced antitumor activities against A549, HT‐29 and MDA‐MB‐231 cell lines compared to dihydroartemisinin.
ChemInform Abstract: Stereoselective Synthesis of β‐Glycosyl Esters of cis‐Cinnamic Acid and Its Derivatives Using Unprotected Glycosyl Donors.
Authors: Matsuo Kazumasa , Nishikawa Keisuke , Shindo Mitsuru 
Published: January 2012

AbstractThe first efficient synthesis of the potent allelochemical (IIIa), isolated from Spiraea thunbergii, using the unprotected Hannesian‐type glycosyl donor (I) is elaborated.
ChemInform Abstract: Highly Facialselective Synthesis of Pyranose 1,3‐Oxazines and Their Ring Opening with Nucleophiles: A Novel Entry to 2‐C‐Branched Glycosides.
Authors: Yin Biao‐Lin , Zhang Ze‐Ren , Xu Li‐Wen , Jiang Huanfeng 
Published: January 2012

AbstractThe reaction of various glycals with N‐benzoyl‐O‐alkylacetals, promoted by TmsOTf, leads to pyranose 1,3‐oxazines structures with high diastereoselectivity.
ChemInform Abstract: Highly Effective Synthesis and Photoluminescence of Sr2Si5N8:Eu2+ Red‐Emitting Phosphor for LEDs.
Authors: Nersisyan Hayk , Won Hyung Il , Won Chang Whan 
Published: January 2012

AbstractThe title phosphor is synthesized by self‐sustaining combustion of SrX2 and EuX3 (X: F, Cl, I), micrometer sized Si powder, polytetrafluoroethylene, and urea under 2.0 MPa N2 pressure.
Atrial Fibrillation and Vascular Disease—A Bad Combination
Authors: Bjerring Olesen Jonas , Gislason Gunnar Hilmar , Torp‐Pedersen Christian , Lip Gregory Y. H. 
Published: January 2012

AbstractThis article provides an overview of (i) the risk of stroke associated with vascular disease (acute coronary syndromes and peripheral artery disease) in patients with atrial fibrillation, (ii) the frequent coexistence of vascular disease in patients with atrial fibrillation and, (iii) the cardiovascular risk associated with the coexisting of the two diseases. The literature on this topic is relatively sparse, and we discuss results from both clinical trials and observational studies.There is a clear indication of an increased stroke risk associated with vascular disease in patients with atrial fibrillation. Indeed, patients with atrial fibrillation often had coexisting vascular disease (around 18%), and the combination of the two diseases substantially increases the risk of future cardiovascular events. The increased risk associated with peripheral artery disease in atrial fibrillation is even more pronounced.Patients with atrial fibrillation and stable vascular disease should be treated with oral anticoagulation only, although when these patients present with acute coronary syndrome and/or undergo coronary stenting, concomitant treatment with antiplatelet drugs is indicated. To guide antithrombotic management in patients with atrial fibrillation, several stroke and bleeding risk prediction schemes have been developed. Clin. Cardiol. 2012 DOI: 10.1002/clc.20955Dr. Olesen received an honorarium through an educational grant from Sanofi Aventis for time and expertise spent writing this article. Dr Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Biotronik, Portola and Boehringer Ingelheim and has been on the speakers bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi‐Aventis. Drs. Gislason and Torp‐Pedersen disclose no conflicts of interest.
Can We Predict the Occurrence of Atrial Fibrillation?
Authors: Schnabel Renate B. 
Published: January 2012

AbstractAtrial fibrillation (AF) is a complex disease with increasing prevalence in an aging population and longer survival with cardiovascular diseases. Whereas most clinical efforts have been aimed at predicting risk of AF sequelae such as stroke and heart failure, little is known on primary prevention. AF risk assessment is complicated by the existence of distinct subtypes of AF, such as lone AF or postoperative AF, in contrast to common AF in the elderly. Due to its often intermittent nature, diagnosing AF can be a challenge. Risk prediction becomes reasonable when specific interventions arise. Due to our limited understanding of AF pathophysiology and substantial lack of specific preventive strategies in the population, modification of the general cardiovascular risk profile has largely remained the only option. Initial attempts at combining established risk factors for AF such as age, sex, hypertension, body mass index, electrocardiographic characteristics, and cardiovascular disease in a risk‐prediction instrument have produced a robust algorithm. However, known risk factors only explain a fraction of the population‐attributable risk of AF, and the search for novel risk indicators is ongoing. More efficient monitoring for electrocardiographic precursors of AF and the field of genomics are evolving areas of AF risk factor research. A better understanding of the underlying substrate of AF will provide targets for prevention. In the future, clinical trials will be needed to establish risk categories, interventions, and their efficacy. Despite a relevant public‐health impact, knowledge on risk prediction and primary prevention of AF is still limited today.There are no conflicts of interest to disclose.
Bensulfuron‐methyl Biodegradation and Microbial Parameters in a Riparian Soil as Affected by Simulated Saltwater Incursion
Authors: Yang Changming , Wang Mengmeng , Cai Wenjuan , Li Jianhua 
Published: January 2012

AbstractSoil salinization due to saltwater incursion, is a major threat to microbial population and thus strongly alters biogeochemical processes in a freshwater riparian of coastal estuary region. An incubation experiment was conducted to investigate the effects of simulated saltwater treatments with different percentages of artificial seawater on biodegradation dynamics of herbicide bensulfuron‐methyl (BSM) and microbial ecophysiological parameters in a riparian soil in Chongming Island, China. The results showed that saltwater addition with 10% seawater significantly increased the biodegradation efficiency of BSM with the lowest residual concentration among all the treatments. However, BSM degradation was markedly decreased in the riparian soil with high levels of saltwater treatment. The half‐lives for 20% and 50% seawater treatments were prolonged by 4.9% and 21.1%, respectively, as compared to no saltwater treatment. Throughout the incubation period, 10% seawater treatment showed significantly stimulating effects on microbial parameters in the BSM‐spiked riparian soil. At the end of incubation experiment, flourescein diacetate (FDA) hydrolysis rate, soil microbial adenosine triphosphate (ATP), and basal soil respiration (BSR) in the BSM‐spiked riparian soil with 10% seawater were 64.2%, 48.9%, and 39.4% higher than those with no saltwater treatment, respectively. In contrast, saltwater treatment with 50% seawater significantly inhibited microbial activities, relative to no saltwater treatment. Especially, FDA hydrolysis rate, microbial ATP, and BSR were decreased by 74.1%, 69.8%, and 63.4%, respectively, as compared to no saltwater treatment. Our data indicate that different levels of simulated saltwater incursion can exert variable effects on microbial ecophysiological parameters, and consequently resulted in the difference in biodegradation dynamics of herbicide in the herbicide‐spiked riparian soil.
Distinct Caenorhabditis elegans HLH‐8/twist‐containing dimers function in the mesoderm
Authors: Philogene Mary C. , Meyers Small Stephany G. , Wang Peng , Corsi Ann K. 
Published: January 2012

AbstractBackground: The Caenorhabditis elegans basic helix‐loop‐helix (bHLH) factor HLH‐8, the single Twist ortholog in the nematode genome, plays important roles in mesoderm development, including M lineage patterning and differentiation of vulval and enteric muscles. HLH‐8 cooperates with HLH‐2, the bHLH E/Daughterless ortholog, to regulate downstream target genes, but it is not known whether HLH‐2 is an obligate partner for all HLH‐8 functions. Results: Using hlh‐2 loss‐of‐function alleles and RNAi, we discovered that HLH‐2 is required in the vulval muscles but not in M patterning or enteric muscle development. Additionally, we found that expressing tethered HLH‐8/HLH‐8 dimers in hlh‐8 null animals rescued M patterning and enteric but not vulval muscle development. Conclusions: These results support a model whereby HLH‐8/HLH‐8 homodimers function in M lineage patterning and enteric muscles and HLH‐8/HLH‐2 heterodimers function in the M‐derived vulval muscles. Interestingly, the different dimers function in the same M lineage cells and the switch in dimer function coincides with vulval muscle differentiation. The use of distinct Twist dimers is evolutionarily conserved, and C. elegans provides a paradigm for future dissection of differential promoter regulation by these dimers at a single cell resolution. Developmental Dynamics 241:481–492, 2012. © 2012 Wiley Periodicals, Inc.
Requirements for Jag1‐Rbpj mediated Notch signaling during early mouse lens development
Authors: Le Tien T. , Conley Kevin W. , Mead Timothy J. , Rowan Sheldon , Yutzey Katherine E. , Brown Nadean L. 
Published: January 2012

AbstractBackground: During vertebrate lens development, the lens placode in the embryonic ectoderm invaginates into a lens vesicle, which then separates from the surface epithelium, followed by two waves of fiber cell differentiation. In the mouse, multiple labs have shown that Jag1‐Notch signaling is critically required during the second wave of lens fiber cell formation. However, Notch signaling appears to play no obvious role during lens induction or morphogenesis, although multiple pathway genes are expressed at these earlier stages. Results: Here, we explored functions for Notch signaling specifically during early lens development, by using the early‐acting AP2α‐Cre driver to delete Jag1 or Rbpj. We found that Jag1 and Rbpj are not required during lens induction, but are necessary for proper lens vesicle separation from the surface ectoderm. Conclusions: We conclude that precise levels of Notch signaling are essential during lens vesicle morphogenesis. In addition, AP2α‐Cre‐mediated deletion of Rbpj resulted in embryos with cardiac outflow tract and liver deformities, and perinatal lethality. Developmental Dynamics 241:493–504, 2012. © 2012 Wiley Periodicals, Inc.
N‐myc downstream regulated gene 1 modulates Wnt‐β‐catenin signalling and pleiotropically suppresses metastasis
Authors: Liu Wen , Xing Fei , Iiizumi‐Gairani Megumi , Okuda Hiroshi , Watabe Misako , Pai Sudha K. , Pandey Puspa R. , Hirota Shigeru , Kobayashi Aya , Mo Yin‐Yuan , Fukuda Koji , Li Yi , Watabe Kounosuke 
Published: January 2012

AbstractWnt signalling has pivotal roles in tumour progression and metastasis; however, the exact molecular mechanism of Wnt signalling in the metastatic process is as yet poorly defined. Here we demonstrate that the tumour metastasis suppressor gene, NDRG1, interacts with the Wnt receptor, LRP6, followed by blocking of the Wnt signalling, and therefore, orchestrates a cellular network that impairs the metastatic progression of tumour cells. Importantly, restoring NDRG1 expression by a small molecule compound significantly suppressed the capability of otherwise highly metastatic tumour cells to thrive in circulation and distant organs in animal models. In addition, our analysis of clinical cohorts data indicate that Wnt+/NDRG−/LRP+ signature has a strong predictable value for recurrence‐free survival of cancer patients. Collectively, we have identified NDRG1 as a novel negative master regulator of Wnt signalling during the metastatic progression, which opens an opportunity to define a potential therapeutic target for metastatic disease.
Full‐scale burning tests on double‐skin façade fires
Authors: Chow C. L. 
Published: January 2012

ABSTRACTFire hazard of an architectural feature with double‐skin façade is a concern. An identified scenario of having a post‐flashover room fire adjacent to the façade was studied experimentally in a rig of 6 m tall. Eight tests of cavity depths including a wide value of 2 m, normal values of 1.5 m and 1 m and a narrow value of 0.5 m under a room flashover fire of 1200 kW were carried out. From the measured air temperature profiles inside the façade cavity, the chance of breaking the interior glass pane above the fire room is therefore very high. Copyright © 2012 John Wiley & Sons, Ltd.
Study of a Single‐Chamber Solid Oxide Fuel Cell Microstack with V‐Shaped Congener‐Electrode‐Facing Configuration
Authors: Tian Y. , Lü Z. , Zhang Y. , Wei B. , Liu M. , Huang X. , Su W. 
Published: January 2012

AbstractSingle‐chamber solid oxide fuel cell (SC‐SOFC) microstacks with V‐Shaped congener‐electrode‐facing configuration were fabricated and operated successfully in a box‐like stainless steel chamber. Two gas channels with small gas inlets were used to transport the fuel and oxygen to the anodes and cathodes, respectively. The temperature of an anode‐facing‐anode two‐cell stack was higher than that of a cathode‐facing‐cathode two‐cell stack during the test procedure. For a three‐cell stack, the cell in the middle region presented the highest power output. The open circuit voltage (OCV) and maximum power output of the three‐cell stack in a gas mixture of 100 sccm N2, 120 sccm CH4, and 80 sccm O2 were 3.0 V and 413 mW, respectively.
Matted nodes: Poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status
Authors: Spector Matthew E. , Gallagher K. Kelly , Light Emily , Ibrahim Mohannad , Chanowski Eric J. , Moyer Jeffrey S. , Prince Mark E. , Wolf Gregory T. , Bradford Carol R. , Cordell Kitrina , McHugh Jonathan B. , Carey Thomas , Worden Francis P. , Eisbruch Avraham , Chepeha Douglas B. ,   The University of Michigan Head Neck Specialized Program of Research Excellence (SPORE) Program
Published: January 2012

AbstractBackgroundDespite better prognosis, there is a group of oropharyngeal squamous cell carcinoma (SCC) human papillomavirus (HPV)+ patients who experience treatment failure and succumb to distant metastasis.MethodsSeventy‐eight previously untreated patients nested in a concurrent chemoradiation protocol were reviewed to correlate patterns of local‐regional tumor extent to distant metastasis. Biomarker assessment was: HPV in situ hybridization and epidermal growth factor receptor (EGFR) immunointensity.ResultsThe 3‐year disease‐specific survival (DSS) for patients presenting with and without matted nodes was 69% and 94%, respectively (p = .003). Matted nodes were a poor prognostic factor independent of T classification, HPV, EGFR, and smoking status. For patients who were HPV+, 7 of 11 died of distant metastasis and 6 of 7 with distant metastasis had matted nodes.ConclusionMatted nodes are a novel marker of poor prognosis in oropharyngeal SCC independent of established prognostic factors. Matted nodes may identify patients at risk for the development of distant metastasis who could benefit from systemic therapy, whereas patients without matted nodes may be candidates for de‐escalation of therapy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012
Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC
Authors: Koren‐Michowitz Maya , Volchek Yulia , Naparstek Elizabeth , Gavish Israel , Levi Itai , Rowe Jacob M. , Shimoni Avichai , Nagler Arnon 
Published: January 2012

AbstractImatinib has been accepted as frontline treatment for patients with chronic myeloid leukaemia (CML), and patients generally receive doses ranging from 400 to 800 mg/day. Previous studies have demonstrated that maintaining imatinib plasma levels (IMPLs) >1000 ng/mL leads to improved responses and long‐term outcomes. However, IMPLs vary among patients because of factors such as drug–drug interactions, adherence, toxicity and differential levels of expression of cellular efflux/influx proteins. In this study, IMPLs were analysed in 191 patients with CML and were compared with achievement of molecular and cytogenetic responses (CyR). IMPLs were also correlated with renal and hepatic dysfunction. Additionally, self‐reported adherence was monitored. The median and mean IMPLs were 994 ng/mL and 1070 ± 686 ng/mL, respectively, with 96 patients (50%) achieving plasma levels >1000 ng/mL. Self‐reported patient compliance was 98%. Patients who achieved a complete CyR (CCyR) had significantly higher IMPLs (1078 ± 545 ng/mL) than those without CyR (827 ± 323 ng/mL, p = 0.045). When grouped together, patients who achieved a CCyR or partial CyR had significantly higher IMPLs than patients who achieved a minimal CyR or did not achieve a CyR (1066 ng/mL vs 814 ng/mL, p = 0.002). There was no significant difference observed in the IMPLs between patients who achieved molecular responses (n = 177) on treatment (major molecular response, 976 ± 385 ng/mL versus complete molecular response, 1138 ± 809 ng/mL, p = 0.387). Mean IMPLs were similar in patients with or without renal or hepatic impairment. Overall, this study confirmed previous reports that higher IMPLs correlate with clinical responses and demonstrated that imatinib exposure did not differ in patients with or without liver and/or renal dysfunction. The use of IMPL testing and patient diaries may be practical tools for the management of imatinib therapy in patients with CML. Copyright © 2012 John Wiley & Sons, Ltd.
Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol
Authors: Oakes Tina Marie Myers , Myers Adam L. , Marangell Lauren B. , Ahl Jonna , Prakash Apurva , Thase Michael E. , Kornstein Susan G. 
Published: January 2012

ObjectiveReturn of functional ability is a central goal in the treatment of major depressive disorder. We conducted two trials with the same protocol that was designed to assess functioning after 8 Weeks of treatment with duloxetine.MethodsThe a priori primary outcome was improvement in the Hamilton Depression Rating Scale (HAMD) item 7 (work/activities). Secondary outcomes included improvement in depressive symptoms assessed by the HAMD Maier subscale, and improvement in functioning assessed by the Sheehan Disability Scale (SDS), and the Social Adaptation Self‐evaluation Scale (SASS). Patients were randomly assigned to duloxetine 60 mg/day (Trial I, n = 257; Trial II, n = 261) or placebo (Trial I, n = 127; Trial II, n = 131). Changes from baseline were analyzed using a mixed‐effects model repeated measures approach.ResultsAt Week 8, duloxetine was superior to placebo in improving HAMD work/activities (p < 0.001) in Trial II, but not Trial I (p = 0.051), and Maier scores (p < 0.01) in both trials. At Week 12, duloxetine was superior to placebo on improving SASS scores in both trials, and the SDS in Trial II.ConclusionTreatment with duloxetine was associated with significant improvement in depressive symptoms compared with placebo, but improvement in HAMD work/activities was inconsistent at 8 weeks. Copyright © 2012 John Wiley & Sons, Ltd.
Medication attitudes and beliefs in patients with psychotic and affective disorders on maintenance treatment
Authors: Ng Chee Hong , Smith Deidre J , King Joel , Ong Susan , Schweitzer Isaac 
Published: January 2012

RationalePatient attitudes and beliefs regarding the cost‐benefits of medications may influence treatment adherence. However, beliefs and attitudes about psychotropic medications have not been well studied across different clinical populations.ObjectiveThis study sought to compare medication attitudes, beliefs, and clinical characteristics in patients with psychotic disorders versus those with affective disorders.MethodClinician‐rated and self‐report measures were used to assess the drug attitudes, beliefs, and clinical features of outpatients with affective and psychotic disorders on stable medications.ResultsThere were no significant differences in the overall medication attitudes and beliefs scores between the clinical groups. The affective group, however, were less likely to believe that medications would prevent hospitalisation (p < 0.05) and were less likely to use an aid as a reminder to take their medication (p < 0.05). Medication attitudes and beliefs were found to have significant correlation with reported side effects (p < 0.01) but not with educational level and duration or severity of illness.ConclusionsPatients with psychotic disorders did not show more negative attitudes or beliefs about medication than those with affective disorders. It would be clinically important that equal care is taken to assess perceived drug side effects, and attitudes and beliefs about medications across diagnostic groups. Copyright © 2012 John Wiley & Sons, Ltd.